ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Biota Pharmaceuticals, Inc. (MM)

Biota Pharmaceuticals, Inc. (MM) (NABI)

10,80
0,00
(0,00%)
Fermé 22 Septembre 10:00PM
0,00
0,00
(0,00%)
Après les heures de négociation: -

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
10,80
Prix Achat
0,00
Prix Vente
0,00
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Clôture Veille
10,80
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

NABI Dernières nouvelles

Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Confe

NEW YORK, July 13 /PRNewswire-FirstCall/ -- Jesup & Lamont, Inc., (AMEX: JLI), a full-service boutique brokerage and investment banking firm serving retail and institutional clients, today...

Chapman Capital Supports Sale of Nabi Biologics Division of Nabi Biopharmaceuticals

Investment Advisor Seeks NicVAX(R) Strategic Partnering LOS ANGELES, June 15 /PRNewswire/ -- Chapman Capital L.L.C., investment advisor to two investment funds that together own 6.6% of the...

Third Point to Proceed with Consent Solicitation to Remove Nabi Biopharmaceuticals' Chairman McLain

NEW YORK, Oct. 4 /PRNewswire/ -- Third Point LLC ("Third Point") confirmed today that it will proceed shortly with its previously-announced plan to conduct a consent solicitation to remove...

Nabi Biopharmaceuticals Initiates Phase IIB "Proof-of-Concept" Study For NicVAX

- Study Designed to Demonstrate Vaccine's Effectiveness in Smoking Cessation; Results Expected Mid-2007 - ROCKVILLE, Md., May 24 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals today announced...

White Mountain Capital Reiterates Buy Rating on Nabi Biopharmaceuticals Ahead of Staphvax Data Release

NANUET, N.Y., Oct. 4 /PRNewswire/ -- Oren Levy, M.D., Ph.D., analyst for independent research provider White Mountain Capital, LLC, reiterated his BUY rating on Nabi Biopharmaceuticals...

Nabi Biopharmaceuticals Announces Altastaph(TM) Phase II Trial Results in Neonates

Nabi Biopharmaceuticals Announces Altastaph(TM) Phase II Trial Results in Neonates Analysis Drives Development of Next Generation Product ROCKVILLE, Md., Nov. 17 /PRNewswire-FirstCall/ -- Nabi...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BNZIBanzai International Inc
US$ 5,645
(96,01%)
61,39M
ZJYLJin Medical International Ltd
US$ 3,975
(50,00%)
1,24M
ANEBAnebulo Pharmaceuticals Inc
US$ 2,9001
(39,43%)
78,85k
XPONExpion360 Inc
US$ 0,081
(39,18%)
1,46B
AENTAlliance Entertainment Holding Corporation
US$ 2,74
(34,31%)
4,23M
GSIWGarden Stage Ltd
US$ 1,34
(-82,89%)
26,44M
CRBPCorbus Pharmaceuticals Holdings Inc
US$ 19,51
(-62,26%)
12,29M
LGCBLinkage Global Inc
US$ 0,4183
(-57,70%)
2,16M
BFIBurgerFi International Inc
US$ 0,0855
(-42,27%)
15,05M
SKYESkye Bioscience Inc
US$ 3,17
(-42,26%)
5,14M
XPONExpion360 Inc
US$ 0,081
(39,18%)
1,46B
NVDANVIDIA Corporation
US$ 116,00
(-1,59%)
378,16M
AAPLApple Inc
US$ 228,20
(-0,29%)
320,24M
INTCIntel Corporation
US$ 21,84
(3,31%)
261,68M
VERBVerb Technology Company Inc
US$ 0,0742
(33,45%)
178,65M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock